Advancing the Dose

Ep. 20 - Diabetes Tech 2026: AID in the Spotlight

Discover key updates, expert insights, and practical tips as we dive into the 2026 ADA Standards of Care for diabetes technology.1 Find out what’s new, what’s changed, and what remains consistent in the ADA’s latest guidelines.
Moderator: Kristen Scavuzzo, MS, RD | Medtronic Diabetes
Speakers: Robert Vigersky, MD, Medtronic Diabetes | Jen McVean, MD, Medtronic Diabetes
 
This podcast is intended for healthcare professionals only.Product usage represented may not be approved or cleared in all markets.
 
Due to inherent data limitations, caution is advised when attempting to extrapolate these results to new patients. There could be significant differences. 1. American Diabetes Association. Diabetes Care. Volume 49, Supplement 1. January 2026. Accessed March 2, 2026. Available at: https://diabetesjournals.org/care/issue/49/Supplement_1 2. American Diabetes Association Professional Practice Committee for Diabetes*; 7. Diabetes Technology: Standards of Care in Diabetes—2026. Diabetes Care 1 January 2026; 49 (Supplement_1): S150–S165. https://doi.org/10.2337/dc26-S0073. Medtronic data on file. Number of users with ≥ 10 days of sensor glucose data; Optimal settings are glucose target at 100 mg/dL and Active Insulin Time at 2 hours and used ≥95% of the time. MiniMed™ 780G data uploaded voluntarily by 334,269 users globally to CareLink™ Personal from 02 January 2020 to 31 July 2025.
 
MINIMED™ 780G SYSTEM WITH SMARTGUARD™ TECHNOLOGY WITH INSTINCT SENSOR, SIMPLERA SYNC™ SENSOR, AND GUARDIAN™ 4 SENSOR
The MiniMed™ 780G system is intended for the continuous delivery of basal insulin at selectable rates and the administration of insulin boluses at selectable rates for the management of type 1 diabetes mellitus in persons 7 years of age and older, and of type 2 diabetes mellitus in persons 18 years of age and older requiring insulin. The system is also intended to continuously monitor glucose values in the fluid under the skin.
The MiniMed™ 780G System includes SmartGuard™ technology, which can be programmed to automatically adjust insulin delivery based on the continuous glucose monitoring (CGM) sensor glucose values and can suspend delivery of insulin when the sensor glucose (SG) value falls below or is predicted to fall below predefined threshold values. The system is intended for use with connected sensors, including the Simplera Sync™ and Guardian™ 4 sensors and integrated continuous glucose monitors, including the Instinct sensor, each of which has different wear-time, form factor, insertion site, and other distinguishing characteristics that relate to sensor performance. Consult the appropriate sensor user guide when using the system. Discuss treatment decisions with your HCP.
WARNING: Do not use the SmartGuard™ feature for people who require less than 8 units or more than 250 units of total daily insulin per day. A total daily dose of at least 8 units, but no more than 250 units, is required to operate in the SmartGuard™ feature.
WARNING: Do not use the MiniMed™ 780G system until appropriate training has been received from a healthcare professional. Training is essential to ensure the safe use of the MiniMed™ 780G system.
WARNING: Do not use SG values to make treatment decisions, including delivering a bolus, while the pump is in Manual Mode. When the SmartGuard™ feature is active and you are no longer in Manual Mode, the pump uses an SG value, when available, to calculate a bolus amount. However, if your symptoms do not match the SG value, use a blood glucose (BG) meter to confirm the SG value. Failure to confirm glucose levels when your symptoms do not match the SG value can result in the infusion of too much or too little insulin, which may cause hypoglycemia or hyperglycemia.
Pump therapy is not recommended for people whose vision or hearing does not allow for the recognition of pump signals, alerts, or alarms. The safety of the MiniMed™ 780G system has not been studied in pregnant women or in persons using other anti-hyperglycemic therapies that do not include insulin. For complete details of the system, including accessories and additional important safety information concerning indications, contraindications, warnings and precautions associated with the system and its components, please consult https://www.medtronicdiabetes.com/important-safety-information#minimed-780g and the appropriate user guide at https://www.medtronicdiabetes.com/download-library

Ep. 19 - A year of impact: MiniMed™ 780G highlights

Kick off the New Year with us as we celebrate the MiniMed™ 780G system research that defined 2025! From compelling discoveries to data that propelled technology forward, get ready for a dynamic recap that inspires and sets the stage for an exciting year ahead!
Moderator: Kristen Scavuzzo, MS, RD | Medtronic Diabetes
Speakers: Robert Vigersky, MD, Medtronic Diabetes | Jen McVean, MD, Medtronic Diabetes
 
This podcast is intended for healthcare professionals only.Product usage represented may not be approved or cleared in all markets.
 
Due to inherent data limitations, caution is advised when attempting to extrapolate these results to new patients. There could be significant differences. 1. Bhargava A., et al. Diabetes Technol & Ther. 2025;27(5): 366-375. http://dx.doi.org/10.1089/dia.2024.05862. Nally LM, et al. Safety and Glycemic Outcomes of the MiniMed™ 780G System with a Disposable All-in-One Sensor. Diabetes Technology and Therapeutics. 18 August 2025 https://doi.org/10.1177/15209156251368928 3. Vigersky, R et al. MiniMed™ 780G system users achieve consensus glycemic goals regardless of size of carbohydrate entry. American Diabetes Association 85th Scientific Sessions | Chicago, IL | June 20th – 23rd, 20254. McVean, J et al. Days without user-initiated boluses: real-world performance of the MiniMed™ 780G system. [A2481] American Diabetes Association 85th Scientific Sessions | Chicago, IL | June 20th – 23rd, 20255. Thijs I, et al. JDST. 2025. Mar 1212:19322968251318373. doi: 10.1177/19322968251318373. Epub ahead of print. PMID: 40071717; PMCID: PMC11954135 6. McVean J, et al. Achieved and Sustained Glycemic Outcomes with Reduction in Burden: Three-year real-world follow up of the MiniMed 780G system. EASD 61st Annual Meeting, Vienna, Austria 15-19 September 2025
 
MINIMED™ 780G SYSTEM WITH SMARTGUARD™ TECHNOLOGY WITH INSTINCT SENSOR, SIMPLERA SYNC™ SENSOR, AND GUARDIAN™ 4 SENSOR
The MiniMed™ 780G system is intended for the continuous delivery of basal insulin at selectable rates and the administration of insulin boluses at selectable rates for the management of type 1 diabetes mellitus in persons 7 years of age and older, and of type 2 diabetes mellitus in persons 18 years of age and older requiring insulin. The system is also intended to continuously monitor glucose values in the fluid under the skin.
The MiniMed™ 780G System includes SmartGuard™ technology, which can be programmed to automatically adjust insulin delivery based on the continuous glucose monitoring (CGM) sensor glucose values and can suspend delivery of insulin when the sensor glucose (SG) value falls below or is predicted to fall below predefined threshold values. The system is intended for use with connected sensors, including the Simplera Sync™ and Guardian™ 4 sensors and integrated continuous glucose monitors, including the Instinct sensor, each of which has different wear-time, form factor, insertion site, and other distinguishing characteristics that relate to sensor performance. Consult the appropriate sensor user guide when using the system. Discuss treatment decisions with your HCP.
WARNING: Do not use the SmartGuard™ feature for people who require less than 8 units or more than 250 units of total daily insulin per day. A total daily dose of at least 8 units, but no more than 250 units, is required to operate in the SmartGuard™ feature.
WARNING: Do not use the MiniMed™ 780G system until appropriate training has been received from a healthcare professional. Training is essential to ensure the safe use of the MiniMed™ 780G system.
WARNING: Do not use SG values to make treatment decisions, including delivering a bolus, while the pump is in Manual Mode. When the SmartGuard™ feature is active and you are no longer in Manual Mode, the pump uses an SG value, when available, to calculate a bolus amount. However, if your symptoms do not match the SG value, use a blood glucose (BG) meter to confirm the SG value. Failure to confirm glucose levels when your symptoms do not match the SG value can result in the infusion of too much or too little insulin, which may cause hypoglycemia or hyperglycemia.
Pump therapy is not recommended for people whose vision or hearing does not allow for the recognition of pump signals, alerts, or alarms. The safety of the MiniMed™ 780G system has not been studied in pregnant women or in persons using other anti-hyperglycemic therapies that do not include insulin. For complete details of the system, including accessories and additional important safety information concerning indications, contraindications, warnings and precautions associated with the system and its components, please consult https://www.medtronicdiabetes.com/important-safety-information#minimed-780g and the appropriate user guide at https://www.medtronicdiabetes.com/download-library

Ep 18: A new era in care for T2D: The rise of AID

Technology for people living with insulin-requiring type 2 diabetes (T2D) is getting a major upgrade. In this episode, dive into how the MiniMed™ 780G system is helping more people with T2D achieve their glycemic goals with less hassle. Discover what the pivotal trial uncovered and why automated insulin delivery (AID) could redefine everyday life for people living with insulin-requiring T2D.
Speakers: Robert Vigersky, MD, Medtronic Diabetes | Pablo Mora, MD, FACE, MSc, CDCES, Tekton Research, LLC North Texas Diabetes and Endocrinology, University of Texas Southwestern
 
This podcast is intended for healthcare professionals only.Product usage represented may not be approved or cleared in all markets.
 
Due to inherent data limitations, caution is advised when attempting to extrapolate these results to new patients. There could be significant differences. 1. Khan MAB, et al. J Epidemiol Glob Health. 2020;10(1):107-111.; 2. International Diabetes Federation. IDF Diabetes Atlas, 13. Bhargava A, et al. Diabetes Technol & Ther. 2025;27(5);366-375. http://dx.doi.org/10.1089/dia.2024.0586
 
Important Safety Information: MINIMED™ 780G SYSTEM WITH SMARTGUARD™ TECHNOLOGY WITH SIMPLERA SYNC™ SENSOR
The MiniMed™ 780G system is intended for the continuous delivery of basal insulin at selectable rates, and the administration of insulin boluses at selectable rates for the management of type 1 diabetes mellitus in persons 7 years of age and older, and of type 2 diabetes mellitus in persons 18 years of age and older requiring insulin. The system is also intended to continuously monitor glucose values in the fluid under the skin. The MiniMed™ 780G system includes SmartGuard™ technology, which can be programmed to automatically adjust insulin delivery based on continuous glucose monitoring (CGM) sensor glucose values and can suspend delivery of insulin when the SG value falls below or is predicted to fall below predefined threshold values.
The Simplera Sync™ sensor can be used one time and has a life up to 6 days, followed by a grace period of 24 hours. During the grace period, the sensor will continue to work as it did during the first 6 days, to allow the patient to change their sensor more flexibly. However, some sensors may not survive the full wear period for a variety of reasons. Please be prepared to replace the sensor during the grace period to ensure sensor glucose values continue to be monitored.
The Simplera Sync™ sensor is not intended to be used directly to make therapy adjustments while the MiniMed™ 780G is operating in manual mode. All therapy adjustments in Manual mode should be based on measurements obtained using a blood glucose meter and not on values provided by the Simplera Sync™ sensor. The Simplera Sync™ sensor has been studied and is approved for use in patients ages 7 years and older and in the arm insertion site only. Do not use the Simplera Sync™ sensor in the abdomen or other body sites, including the buttocks, due to unknown or different performance that could result in hypoglycemia or hyperglycemia.
The Medtronic MiniMed™ 780G System consists of the following devices: MiniMed™ 780G Insulin Pump, Simplera Sync™ sensor, the Accu-Chek™ Guide Link blood glucose meter, and the Accu-Chek™ Guide Test Strips. The system requires a prescription from a healthcare professional.
WARNING: Do not use the SmartGuard™ feature for people who require less than 8 units or more than 250 units of total daily insulin per day. A total daily dose of at least 8 units, but no more than 250 units, is required to operate in the SmartGuard™ feature.
WARNING: Do not use the MiniMed™ 780G system until appropriate training has been received from a healthcare professional. Training is essential to ensure the safe use of the MiniMed™ 780G system.
WARNING: Do not use SG values to make treatment decisions, including delivering a bolus, while the pump is in Manual Mode. When the SmartGuard™ feature is active and you are no longer in Manual Mode, the pump uses an SG value, when available, to calculate a bolus amount. However, if your symptoms do not match the SG value, use a blood glucose (BG) meter to confirm the SG value. Failure to confirm glucose levels when your symptoms do not match the SG value can result in the infusion of too much or too little insulin, which may cause hypoglycemia or hyperglycemia.
Pump therapy is not recommended for people whose vision or hearing does not allow for the recognition of pump signals, alerts, or alarms. The safety of the MiniMed™ 780G system has not been studied in pregnant women or in persons using other anti-hyperglycemic therapies that do not include insulin. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, please consult https://www.medtronicdiabetes.com/important-safety-information#minimed-780g and the appropriate user guide at https://www.medtronicdiabetes.com/download-library
Important Safety Information: MINIMED™ 780G SYSTEM WITH SMARTGUARD™ TECHNOLOGY WITH GUARDIAN™ 4 SENSOR
The MiniMed™ 780G system is intended for the continuous delivery of basal insulin at selectable rates, and the administration of insulin boluses at selectable rates for the management of type 1 diabetes mellitus in persons 7 years of age and older, and of type 2 diabetes mellitus in persons 18 years of age and older requiring insulin. The system is also intended to continuously monitor glucose values in the fluid under the skin. The MiniMed™ 780G system includes SmartGuard™ technology, which can be programmed to automatically adjust insulin delivery based on continuous glucose monitoring (CGM) sensor glucose values and can suspend delivery of insulin when the SG value falls below or is predicted to fall below predefined threshold values.
The Medtronic MiniMed™ 780G system consists of the following devices: MiniMed™ 780G Insulin Pump, the Guardian™ 4 Transmitter, the Guardian™ 4 Sensor, One-press serter, the Accu-Chek™ Guide Link blood glucose meter, and the Accu-Chek™ Guide Test Strips. The system requires a prescription from a healthcare professional.
The Guardian™ 4 Sensor is intended for use with the MiniMed™ 780G system and the Guardian 4 transmitter to monitor glucose levels for the management of diabetes. The sensor is intended for single use and requires a prescription. The Guardian™ (4) sensor is indicated for up to seven days of continuous use.
The Guardian™ 4 sensor is not intended to be used directly to make therapy adjustments while the MiniMed™ 780G is operating in manual mode. All therapy adjustments in manual mode should be based on measurements obtained using a blood glucose meter and not on values provided by the Guardian™ 4 sensor. The Guardian™ 4 sensor has been studied and is approved for use in patients ages 7 years and older and in the arm insertion site only. Do not use the Guardian™ 4 sensor in the abdomen or other body sites including the buttocks, due to unknown or different performance that could result in hypoglycemia or hyperglycemia.
WARNING: Do not use the SmartGuard™ feature for people who require less than 8 units or more than 250 units of total daily insulin per day. A total daily dose of at least 8 units, but no more than 250 units, is required to operate in the SmartGuard™ feature.
WARNING: Do not use the MiniMed™ 780G system until appropriate training has been received from a healthcare professional. Training is essential to ensure the safe use of the MiniMed™ 780G system.
WARNING: Do not use SG values to make treatment decisions, including delivering a bolus, while the pump is in Manual Mode. When the SmartGuard™ feature is active and you are no longer in Manual Mode, the pump uses an SG value, when available, to calculate a bolus amount. However, if your symptoms do not match the SG value, use a BG meter to confirm the SG value. Failure to confirm glucose levels when your symptoms do not match the SG value can result in the infusion of too much or too little insulin, which may cause hypoglycemia or hyperglycemia.
Pump therapy is not recommended for people whose vision or hearing does not allow for the recognition of pump signals, alerts, or alarms. The safety of the MiniMed™ 780G system has not been studied in pregnant women or in persons using other anti-hyperglycemic therapies that do not include insulin. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, please consult https://www.medtronicdiabetes.com/important-safety-information#minimed-780g and the appropriate user guide at https://www.medtronicdiabetes.com/download-library

Ep. 17: Transforming MDI with InPen

Multiple daily injections (MDI) doesn't have to stay stuck in the past. Discover how the InPen™ system is transforming multiple daily injections - bringing smart, connected support to simplify MDI.
Speakers: Robert Vigersky, MD, Medtronic Diabetes | Nana-Hawa Yayah Jones, MD, Cincinnati Children’s Hospital Medical Center
 
This podcast is intended for healthcare professionals only.Product usage represented may not be approved or cleared in all markets.
 
Important Safety Information
The InPen system, consisting of a mobile app and home-use reusable pen injector, requires a prescription. It is for single-patient use by people with diabetes under the supervision of an adult caregiver, or by a patient age 7 and older for the self-injection of a desired dose of insulin.
The pen injector is compatible with Lilly Humalog® U-100 3.0 mL cartridges, Novo Nordisk Novolog® U-100 3.0 mL cartridges, and Novo Nordisk Fiasp® U-100 3.0 mL cartridges and single-use detachable and disposable pen needles (not included). The pen injector allows the user to dial the desired dose from 0.5 to 30 units in one-half (1/2) unit increments.
The InPen system dose calculator, a component of the InPen system app, is indicated for the management of diabetes by people with diabetes under the supervision of an adult caregiver, or by a patient age 7 and older for calculating an insulin dose or carbohydrate intake based on user entered data.
For an insulin dose based on amount of carbohydrates, a healthcare professional must provide patient-specific target blood glucose, insulin-to-carbohydrate ratio, and insulin sensitivity parameters to be programmed into the software prior to use.
For an insulin dose based on fixed/variable meal sizes, a healthcare professional must provide patient-specific fixed doses/meal sizes to be programmed into the software prior to use.
For additional product and important safety considerations, see User Guide and https://bit.ly/InPenSafety
Connectivity, proper settings and user interaction required, including manual logging of rapid-acting insulin given by other means. WARNING: not doing so may lead to hypoglycemia, which could result in serious injury or death.

Ep. 16: Unveiling the Instinct sensor

With FDA clearance of the MiniMed™ 780G system featuring the new Instinct sensor, made exclusively for MiniMed by Abbott, go behind the scenes with two of the brilliant engineering minds driving innovation and the future of diabetes technology at Medtronic Diabetes.
Speakers: Kristen Scavuzzo, MS, RD, Medtronic Diabetes | Ali Dianaty, Medtronic Diabetes | Lou Lintereur, Medtronic Diabetes
 
This podcast is intended for healthcare professionals only.Product usage represented may not be approved or cleared in all markets.
 
Due to inherent data limitations, caution is advised when attempting to extrapolate these results to new patients. There could be significant differences. 1. Data on File, Abbott Diabetes Care, Inc.2. Alva, Shridhara, Ronald Brazg, Kristin Castorino, Mark Kipnes, David R. Liljenquist, and Hanqing Liu. "Accuracy of the Third Generation of a 14-Day Continuous Glucose Monitoring System." Diabetes Therapy 14, no. 4 (2023): 767-776.
©2025 Medtronic. MiniMed and MiniMed logo are trademarks of Medtronic MiniMed, Inc. The sensor shape and appearance, Abbott, and “a” logo are marks and/or designs of the Abbott group of companies in various territories and used under license. Sensor image ©2025 Abbott. ™*Third–party brands are trademarks of their respective owners.
Important Safety Information: Medtronic MiniMed™ 780G System With SmartGuard™ Technology with Instinct sensor
The MiniMed™ 780G system is intended for continuous delivery of basal insulin at selectable rates, and the administration of insulin boluses at selectable amounts for the management of type 1 diabetes mellitus in persons seven years of age and older requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed™ 780G System includes SmartGuard™ technology, which can be programmed to automatically adjust insulin delivery based on the continuous glucose monitoring (CGM) sensor glucose values and can suspend delivery of insulin when the sensor glucose (SG) value falls below or is predicted to fall below predefined threshold values.
The Instinct sensor can be used one time and has a life up to 15 days. The Instinct sensor is not intended to be used directly to make therapy adjustments while the MiniMed™ 780G system is operating in manual mode. All therapy adjustments in Manual mode should be based on measurements obtained using a blood glucose meter and not on values provided by the Instinct sensor. The Instinct sensor has been studied and is approved for use in patients ages 7 years and older and in the arm insertion site only. Only apply the sensor to the back of your upper arm. The sensor may not work properly in other areas.
The Medtronic MiniMed™ 780G System consists of the following devices: MiniMed™ 780G Insulin Pump and the Instinct sensor. The system requires a prescription from a healthcare professional.
WARNING: Do not use the SmartGuard™ feature for people who require less than 8 units or more than 250 units of total daily insulin per day. A total daily dose of at least 8 units, but no more than 250 units, is required to operate in the SmartGuard™ feature.
WARNING: Do not use the MiniMed™ 780G system until appropriate training has been received from a healthcare professional. Training is essential to ensure the safe use of the MiniMed™ 780G system.
WARNING: Do not use SG values to make treatment decisions, including delivering a bolus, while the pump is in Manual Mode. When the SmartGuard™ feature is active and you are no longer in Manual Mode, the pump uses an SG value, when available, to calculate a bolus amount. However, if your symptoms do not match the SG value, use a blood glucose (BG) meter to confirm the SG value. Failure to confirm glucose levels when your symptoms do not match the SG value can result in the infusion of too much or too little insulin, which may cause hypoglycemia or hyperglycemia.
Pump therapy is not recommended for people whose vision or hearing does not allow for the recognition of pump signals, alerts, or alarms. The safety of the MiniMed™ 780G system has not been studied in pregnant women, persons with type 2 diabetes, or in persons using other anti-hyperglycemic therapies that do not include insulin. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, please consult https://www.medtronicdiabetes.com/important-safety-information#minimed-780g and the appropriate user guide at https://www.medtronicdiabetes.com/download-library
Important Safety Information: Medtronic MiniMed™ 780G System With SmartGuard™ Technology with Simplera Sync™ sensor
The MiniMed™ 780G system is intended for the continuous delivery of basal insulin at selectable rates, and the administration of insulin boluses at selectable rates for the management of type 1 diabetes mellitus in persons 7 years of age and older, and of type 2 diabetes mellitus in persons 18 years of age and older requiring insulin. The system is also intended to continuously monitor glucose values in the fluid under the skin. The MiniMed™ 780G system includes SmartGuard™ technology, which can be programmed to automatically adjust insulin delivery based on continuous glucose monitoring (CGM) sensor glucose values and can suspend delivery of insulin when the SG value falls below or is predicted to fall below predefined threshold values.
The Simplera Sync™ sensor can be used one time and has a life up to 6 days, followed by a grace period of 24 hours. During the grace period, the sensor will continue to work as it did during the first 6 days, to allow the patient to change their sensor more flexibly. However, some sensors may not survive the full wear period for a variety of reasons. Please be prepared to replace the sensor during the grace period to ensure sensor glucose values continue to be monitored.
The Simplera Sync™ sensor is not intended to be used directly to make therapy adjustments while the MiniMed™ 780G is operating in manual mode. All therapy adjustments in Manual mode should be based on measurements obtained using a blood glucose meter and not on values provided by the Simplera Sync™ sensor. The Simplera Sync™ sensor has been studied and is approved for use in patients ages 7 years and older and in the arm insertion site only. Do not use the Simplera Sync™ sensor in the abdomen or other body sites, including the buttocks, due to unknown or different performance that could result in hypoglycemia or hyperglycemia.
The Medtronic MiniMed™ 780G System consists of the following devices: MiniMed™ 780G Insulin Pump, Simplera Sync™ sensor, the Accu-Chek™ Guide Link blood glucose meter, and the Accu-Chek™ Guide Test Strips. The system requires a prescription from a healthcare professional.
WARNING: Do not use the SmartGuard™ feature for people who require less than 8 units or more than 250 units of total daily insulin per day. A total daily dose of at least 8 units, but no more than 250 units, is required to operate in the SmartGuard™ feature.
WARNING: Do not use the MiniMed™ 780G system until appropriate training has been received from a healthcare professional. Training is essential to ensure the safe use of the MiniMed™ 780G system.
WARNING: Do not use SG values to make treatment decisions, including delivering a bolus, while the pump is in Manual Mode. When the SmartGuard™ feature is active and you are no longer in Manual Mode, the pump uses an SG value, when available, to calculate a bolus amount. However, if your symptoms do not match the SG value, use a blood glucose (BG) meter to confirm the SG value. Failure to confirm glucose levels when your symptoms do not match the SG value can result in the infusion of too much or too little insulin, which may cause hypoglycemia or hyperglycemia.
Pump therapy is not recommended for people whose vision or hearing does not allow for the recognition of pump signals, alerts, or alarms. The safety of the MiniMed™ 780G system has not been studied in pregnant women or in persons using other anti-hyperglycemic therapies that do not include insulin. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, please consult https://www.medtronicdiabetes.com/important-safety-information#minimed-780g and the appropriate user guide at https://www.medtronicdiabetes.com/download-library

Ep. 15: Adapting to real life: how the MiniMed™ 780G system responds to glycemic variability

Explore how the MiniMed™ 780G system adapts in real time to life's messiness - and what the latest data reveals about its power to simplify even the most complicated days.
Speakers: Kristen Scavuzzo, MS, RD, Medtronic Diabetes | Robert Vigersky, MD, Medtronic Diabetes
 
This podcast is intended for healthcare professionals only.Product usage represented may not be approved or cleared in all markets.
 
*510k pending for Medtronic interoperable system; currently under review by FDA; not available for sale or distribution in the U.S.Due to inherent data limitations, caution is advised when attempting to extrapolate these results to new patients. There could be significant differences. 1. Tack CJ, et al. JMR Diabetes. 2018;3(4);e17 doi.org/10.2196/diabetes.2. DiaTribeLearn. Making Sense of Diabetes. https://diatribe.org/diabetes-management/42-factors-affect-blood-glucose-surprising-update. Accessed Feb 28, 2025 3. Elhenawy YI, Kader MSA, Thabet RA. Diabetes Obes Metab. 2024 Nov;26(11):4916:4923. Doi:10.1111/dom.15891 4. Shin J et al. Significant Reduction in Real-world Nighttime Burden with the MiniMed(TM) 780G System. Poster presented at: American Diabetes Association 84th Scientific Sessions; June 21-24, 2024; Orlando, Florida.5. McVean J et al. Hyperglycemia from Real-World Dawn Phenomenom is Nearly Eliminated with the MiniMed(TM) 780G system. Poster presented at: American Diabetes Association 84th Scientific Session; June 21-24, 2024; Orlando, Florida.6. Tinti D., et al. Diabetes Obes Metab. 2025;1-4. 7. McVean, J et al. Stable glycemic control in or out of school in children using the MiniMed™ 780G system – a real-world study from Italy. Poster presented at ISPAD (International Society for Pediatric and Adolescent Diabetes). October 16-19, 2024; Lisobn, Portugal. 8. Elbarbary NS., Ismail EAR. Diabetes Research and Clinical Practice. 2025. https://doi.org/10.1016/j.diabres.2025.112042 9. Al-Sofiana ME., et al. Diabetes Obes Metab. 2023; 1-13.
Important Safety Information: Medtronic MiniMed™ 780G System With SmartGuard™ Technology with Simplera Sync™ sensor
The MiniMed™ 780G system is intended for continuous delivery of basal insulin at selectable rates, and the administration of insulin boluses at selectable amounts for the management of type 1 diabetes mellitus in persons seven years of age and older requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed™ 780G System includes SmartGuard™ technology, which can be programmed to automatically adjust insulin delivery based on the continuous glucose monitoring (CGM) sensor glucose values and can suspend delivery of insulin when the SG value falls below or is predicted to fall below predefined threshold values.
The Simplera Sync™ sensor can be used one time and has a life up to 6 days, followed by a grace period of 24 hours. During the grace period, the sensor will continue to work as it did during the first 6 days, to allow the patient to change their sensor more flexibly. However, some sensors may not survive the full wear period for a variety of reasons. Please be prepared to replace the sensor during the grace period to ensure sensor glucose values continue to be monitored.
The Simplera Sync™ sensor is not intended to be used directly to make therapy adjustments while the MiniMed 780G is operating in manual mode. All therapy adjustments in Manual mode should be based on measurements obtained using a blood glucose meter and not on values provided by the Simplera Sync™ sensor. The Simplera Sync™ sensor has been studied and is approved for use in patients ages 7 years and older and in the arm insertion site only. Do not use the Simplera Sync™ sensor in the abdomen or other body sites, including the buttocks, due to unknown or different performance that could result in hypoglycemia or hyperglycemia.
The Medtronic MiniMed™ 780G System consists of the following devices: MiniMed™ 780G Insulin Pump, Simplera Sync™ sensor, the Accu-Chek™Guide Link blood glucose meter, and the Accu-Chek™Guide Test Strips. The system requires a prescription from a healthcare professional.
WARNING: Do not use the SmartGuard™ feature for people who require less than 8 units or more than 250 units of total daily insulin per day. A total daily dose of at least 8 units, but no more than 250 units, is required to operate in the SmartGuard™ feature.
WARNING: Do not use the MiniMed™ 780G system until appropriate training has been received from a healthcare professional. Training is essential to ensure the safe use of the MiniMed™ 780G system.
WARNING: Do not use SG values to make treatment decisions, including delivering a bolus, while the pump is in Manual Mode. When the SmartGuard™ feature is active and you are no longer in Manual Mode, the pump uses an SG value, when available, to calculate a bolus amount. However, if your symptoms do not match the SG value, use a BG meter to confirm the SG value. Failure to confirm glucose levels when your symptoms do not match the SG value can result in the infusion of too much or too little insulin, which may cause hypoglycemia or hyperglycemia.
Pump therapy is not recommended for people whose vision or hearing does not allow for the recognition of pump signals, alerts, or alarms. The safety of the MiniMed™ 780G system has not been studied in pregnant women, persons with type 2 diabetes, or in persons using other anti-hyperglycemic therapies that do not include insulin. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with the system and its components, please consult https://www.medtronicdiabetes.com/important-safety-information#minimed-780g and the appropriate user guide at https://www.medtronicdiabetes.com/download-library

Ep. 14: Not all AID systems are the same - a closer look at the MiniMed™ 780G system

Explore how the MiniMed™ 780G system is designed to impact glycemic outcomes and reduce daily burden through the SmartGuard™ algorithm.
Speakers: Kristen Scavuzzo, MS, RD, Medtronic Diabetes | Robert Vigersky, MD, Medtronic Diabetes | Jen McVean, MD, Medtronic Diabetes
 
This podcast is intended for healthcare professionals only.Product usage represented may not be approved or cleared in all markets.
 
Due to inherent data limitations, caution is advised when attempting to extrapolate these results to new patients. There could be significant differences. 1. Choudhary P., et al. Diabetes Technol Ther. 2024; 26(3): S32-37.2. Ebekozien O, Mungmode A, Sanchez J, Rompicherla S, Demeterco-Berggren C, Weinstock RS, Jacobsen LM, Davis G, McKee A, Akturk HK, Maahs DM, Kamboj MK. Longitudinal Trends in Glycemic Outcomes and Technology Use for Over 48,000 People with Type 1 Diabetes (2016-2022) from the T1D Exchange Quality Improvement Collaborative. Diabetes Technol Ther. 2023 Nov;25(11):765-773. doi: 10.1089/dia.2023.0320. Epub 2023 Oct 16. PMID: 37768677. 3. McVean J et al. Hyperglycemia from Real-World Dawn Phenomenon is Nearly Eliminated with the MiniMed™ 780G system. Poster presented at: American Diabetes Association 84th Scientific Sessions; June 21-24, 2024. Orlando, Florida. 4. Zhang JY, et al. Advances in Insulin Pump Infusion Sets Symposium Report. Journal of Diabetes Science and Technology 2021; DOI: 10.1177/1932296821999080 5. Chattaraj S, et al. Study of insulin stability impact on pump therapy: Test model development. Diabetes. 2020;69 (Supplement 1):1012-P 6. Zhang G, et al. Assessment of adhesive patches for an extended-wear infusion set. Diabetes. 2020;69 (Supplement 1):986-P 7. Chattaraj S, et al. The Medtronic extended-wear infusion set: Determining mechanisms of action. As presented at the 14th International Conference on Advanced Technologies & Treatments for Diabetes; June 2-5, 2021. 8. Chattaraj S, et al. 1167-P - CSII and Insulin: does extending the wear duration of infusion sets save expensive insulin? 80th ADA International conference June 2020.
Important Safety Information: Medtronic MiniMed™ 780G System With SmartGuard™ Technology with Simplera Sync™ sensor
The MiniMed™ 780G system is intended for continuous delivery of basal insulin at selectable rates, and the administration of insulin boluses at selectable amounts for the management of type 1 diabetes mellitus in persons seven years of age and older requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed™ 780G System includes SmartGuard™ technology, which can be programmed to automatically adjust insulin delivery based on the continuous glucose monitoring (CGM) sensor glucose values and can suspend delivery of insulin when the SG value falls below or is predicted to fall below predefined threshold values.
The Simplera Sync™ sensor can be used one time and has a life up to 6 days, followed by a grace period of 24 hours. During the grace period, the sensor will continue to work as it did during the first 6 days, to allow the patient to change their sensor more flexibly. However, some sensors may not survive the full wear period for a variety of reasons. Please be prepared to replace the sensor during the grace period to ensure sensor glucose values continue to be monitored.
The Simplera Sync™ sensor is not intended to be used directly to make therapy adjustments while the MiniMed 780G is operating in manual mode. All therapy adjustments in Manual mode should be based on measurements obtained using a blood glucose meter and not on values provided by the Simplera Sync™ sensor. The Simplera Sync™ sensor has been studied and is approved for use in patients ages 7 years and older and in the arm insertion site only. Do not use the Simplera Sync™ sensor in the abdomen or other body sites, including the buttocks, due to unknown or different performance that could result in hypoglycemia or hyperglycemia.
The Medtronic MiniMed™ 780G System consists of the following devices: MiniMed™ 780G Insulin Pump, Simplera Sync™ sensor, the Accu-Chek™Guide Link blood glucose meter, and the Accu-Chek™Guide Test Strips. The system requires a prescription from a healthcare professional.
WARNING: Do not use the SmartGuard™ feature for people who require less than 8 units or more than 250 units of total daily insulin per day. A total daily dose of at least 8 units, but no more than 250 units, is required to operate in the SmartGuard™ feature.
WARNING: Do not use the MiniMed™ 780G system until appropriate training has been received from a healthcare professional. Training is essential to ensure the safe use of the MiniMed™ 780G system.
WARNING: Do not use SG values to make treatment decisions, including delivering a bolus, while the pump is in Manual Mode. When the SmartGuard™ feature is active and you are no longer in Manual Mode, the pump uses an SG value, when available, to calculate a bolus amount. However, if your symptoms do not match the SG value, use a BG meter to confirm the SG value. Failure to confirm glucose levels when your symptoms do not match the SG value can result in the infusion of too much or too little insulin, which may cause hypoglycemia or hyperglycemia.
Pump therapy is not recommended for people whose vision or hearing does not allow for the recognition of pump signals, alerts, or alarms. The safety of the MiniMed™ 780G system has not been studied in pregnant women, persons with type 2 diabetes, or in persons using other anti-hyperglycemic therapies that do not include insulin. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with the system and its components, please consult https://www.medtronicdiabetes.com/important-safety-information#minimed-780g and the appropriate user guide at https://www.medtronicdiabetes.com/download-library

Episode 13: Reducing mealtime stress with AID

Mealtime can be challenging for people living with type 1 diabetes. Learn how the MiniMed™ 780G system’s Meal Detection™ technology works and how this advanced feature can help reduce post-meal hyperglycemia and ease the burden of mealtimes.
Speakers: Robert Vigersky, MD, Medtronic Diabetes | Viral Shah, MD, Indiana University
 
This podcast is intended for healthcare professionals only. Dr. Shah is a paid consultant with Medtronic. Dr. Shah’s comments refer to his experience in his own research and clinical practice. Individual results may vary.Product usage represented may not be approved or cleared in all markets.
 
Automated insulin delivery (AID)† Taking a bolus 15-20 minutes before a meal helps to keep blood sugar levels under control after eating.
Important Safety Information: MiniMed™ 780G system with SmartGuard™ Technology with Guardian™ 4 sensor
The MiniMed™ 780G system is intended for continuous delivery of basal insulin at selectable rates, and the administration of insulin boluses at selectable amounts for the management of type 1 diabetes mellitus in persons seven years of age and older requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed™ 780GSystem includes SmartGuard™ technology, which can be programmed to automatically adjust insulin delivery based on the continuous glucose monitoring (CGM) sensor glucose values and can suspend delivery of insulin when the SG value falls below or is predicted to fall below predefined threshold values.
The Medtronic MiniMed™ 780G System consists of the following devices: MiniMed™ 780G Insulin Pump, the Guardian™ 4 Transmitter, the Guardian™ 4 Sensor, One-press serter, the Accu-Chek™ Guide Link blood glucose meter, and the Accu-Chek™ Guide Test Strips. The system requires a prescription from a healthcare professional.
The Guardian™ 4 Sensor is intended for use with the MiniMed™ 780G system and the Guardian 4 transmitter to monitor glucose levels for the management of diabetes. The sensor is intended for single use and requires a prescription. The Guardian™ (4) sensor is indicated for up to seven days of continuous use.
The Guardian™ 4 sensor is not intended to be used directly to make therapy adjustments while the MiniMed™ 780G is operating in manual mode. All therapy adjustments in manual mode should be based on measurements obtained using a blood glucose meter and not on values provided by the Guardian™ 4 sensor. The Guardian™ 4 sensor has been studied and is approved for use in patients ages 7 years and older and in the arm insertion site only. Do not use the Guardian™ 4 sensor in the abdomen or other body sites including the buttocks, due to unknown or different performance that could result in hypoglycemia or hyperglycemia.
WARNING: Do not use the SmartGuard™ feature for people who require less than 8 units or more than 250 units of total daily insulin per day. A total daily dose of at least 8 units, but no more than 250 units, is required to operate in the SmartGuard™ feature.
WARNING: Do not use the MiniMed™ 780G system until appropriate training has been received from a healthcare professional. Training is essential to ensure the safe use of the MiniMed™ 780G system.
WARNING: Do not use SG values to make treatment decisions, including delivering a bolus, while the pump is in Manual Mode. When the SmartGuard™ feature is active and you are no longer in Manual Mode, the pump uses an SG value, when available, to calculate a bolus amount. However, if your symptoms do not match the SG value, use a BG meter to confirm the SG value. Failure to confirm glucose levels when your symptoms do not match the SG value can result in the infusion of too much or too little insulin, which may cause hypoglycemia or hyperglycemia.
Pump therapy is not recommended for people whose vision or hearing does not allow for the recognition of pump signals, alerts, or alarms. The safety of the MiniMed™ 780G system has not been studied in pregnant women, persons with type 2 diabetes, or in persons using other anti-hyperglycemic therapies that do not include insulin. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, please consult https://www.medtronicdiabetes.com/important-safety-information#minimed-780g and the appropriate user guide at https://www.medtronicdiabetes.com/download-library

Episode 12: Managing activity: exercising on AID

Type 1 diabetes doesn’t have to be a barrier to physical activity. Take a deep dive into the new consensus guidelines developed for individuals using automated insulin delivery systems.
Speakers: Robert Vigersky, MD, Medtronic Diabetes | Gregory Forlenza, MD, Barbara Davis Center
 
This podcast is intended for healthcare professionals only.Product usage represented may not be approved or cleared in all markets.
 
1 Moser, O., Zaharieva, D.P., Adolfsson, P. et al. The use of automated insulin delivery around physical activity and exercise in type 1 diabetes: a position statement of the European Association for the Study of Diabetes (EASD) and the International Society for Pediatric and Adolescent Diabetes (ISPAD). Diabetologia 68, 255–280 (2025). https://doi.org/10.1007/s00125-024-06308-z
Important Safety Information: MiniMed™ 780G system with SmartGuard™ Technology with Guardian™ 4 sensor
The MiniMed™ 780G system is intended for continuous delivery of basal insulin at selectable rates, and the administration of insulin boluses at selectable amounts for the management of type 1 diabetes mellitus in persons seven years of age and older requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed™ 780GSystem includes SmartGuard™ technology, which can be programmed to automatically adjust insulin delivery based on the continuous glucose monitoring (CGM) sensor glucose values and can suspend delivery of insulin when the SG value falls below or is predicted to fall below predefined threshold values.
The Medtronic MiniMed™ 780G System consists of the following devices: MiniMed™ 780G Insulin Pump, the Guardian™ 4 Transmitter, the Guardian™ 4 Sensor, One-press serter, the Accu-Chek™ Guide Link blood glucose meter, and the Accu-Chek™ Guide Test Strips. The system requires a prescription from a healthcare professional.
The Guardian™ 4 Sensor is intended for use with the MiniMed™ 780G system and the Guardian 4 transmitter to monitor glucose levels for the management of diabetes. The sensor is intended for single use and requires a prescription. The Guardian™ (4) sensor is indicated for up to seven days of continuous use.
The Guardian™ 4 sensor is not intended to be used directly to make therapy adjustments while the MiniMed™ 780G is operating in manual mode. All therapy adjustments in manual mode should be based on measurements obtained using a blood glucose meter and not on values provided by the Guardian™ 4 sensor. The Guardian™ 4 sensor has been studied and is approved for use in patients ages 7 years and older and in the arm insertion site only. Do not use the Guardian™ 4 sensor in the abdomen or other body sites including the buttocks, due to unknown or different performance that could result in hypoglycemia or hyperglycemia.
WARNING: Do not use the SmartGuard™ feature for people who require less than 8 units or more than 250 units of total daily insulin per day. A total daily dose of at least 8 units, but no more than 250 units, is required to operate in the SmartGuard™ feature.
WARNING: Do not use the MiniMed™ 780G system until appropriate training has been received from a healthcare professional. Training is essential to ensure the safe use of the MiniMed™ 780G system.
WARNING: Do not use SG values to make treatment decisions, including delivering a bolus, while the pump is in Manual Mode. When the SmartGuard™ feature is active and you are no longer in Manual Mode, the pump uses an SG value, when available, to calculate a bolus amount. However, if your symptoms do not match the SG value, use a BG meter to confirm the SG value. Failure to confirm glucose levels when your symptoms do not match the SG value can result in the infusion of too much or too little insulin, which may cause hypoglycemia or hyperglycemia.
Pump therapy is not recommended for people whose vision or hearing does not allow for the recognition of pump signals, alerts, or alarms. The safety of the MiniMed™ 780G system has not been studied in pregnant women, persons with type 2 diabetes, or in persons using other anti-hyperglycemic therapies that do not include insulin. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, please consult https://www.medtronicdiabetes.com/important-safety-information#minimed-780g and the appropriate user guide at https://www.medtronicdiabetes.com/download-library

Ep. 11: Optimizing MiniMed™ 780G performance with system settings

Automated insulin delivery systems are sophisticated but managing them doesn’t have to be! Learn how to easily optimize settings on the MiniMed™ 780G system.
Speakers: Robert Vigersky, MD, Medtronic Diabetes | Kristen Scavuzzo, MS, RD, Medtronic Diabetes
 
This podcast is intended for healthcare professionals only.Product usage represented may not be approved or cleared in all markets.
 
1 Carlson AL, et al. Diabetes Technol Ther. 2021. Epub 2021/10/26 doi: 10.1089/dia2021.0319. PubMed PMID: 34694909
2 Coudhary, P. et al. Diabetes Technol Ther. 2024 : 26(3) : S32-S37
Important Safety Information: MiniMed™ 780G system with SmartGuard™ Technology with Guardian™ 4 sensor
The MiniMed™ 780G system is intended for continuous delivery of basal insulin at selectable rates, and the administration of insulin boluses at selectable amounts for the management of type 1 diabetes mellitus in persons seven years of age and older requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed™ 780GSystem includes SmartGuard™ technology, which can be programmed to automatically adjust insulin delivery based on the continuous glucose monitoring (CGM) sensor glucose values and can suspend delivery of insulin when the SG value falls below or is predicted to fall below predefined threshold values.
The Medtronic MiniMed™ 780G System consists of the following devices: MiniMed™ 780G Insulin Pump, the Guardian™ 4 Transmitter, the Guardian™ 4 Sensor, One-press serter, the Accu-Chek™ Guide Link blood glucose meter, and the Accu-Chek™ Guide Test Strips. The system requires a prescription from a healthcare professional.
The Guardian™ 4 Sensor is intended for use with the MiniMed™ 780G system and the Guardian 4 transmitter to monitor glucose levels for the management of diabetes. The sensor is intended for single use and requires a prescription. The Guardian™ (4) sensor is indicated for up to seven days of continuous use.
The Guardian™ 4 sensor is not intended to be used directly to make therapy adjustments while the MiniMed™ 780G is operating in manual mode. All therapy adjustments in manual mode should be based on measurements obtained using a blood glucose meter and not on values provided by the Guardian™ 4 sensor. The Guardian™ 4 sensor has been studied and is approved for use in patients ages 7 years and older and in the arm insertion site only. Do not use the Guardian™ 4 sensor in the abdomen or other body sites including the buttocks, due to unknown or different performance that could result in hypoglycemia or hyperglycemia.
WARNING: Do not use the SmartGuard™ feature for people who require less than 8 units or more than 250 units of total daily insulin per day. A total daily dose of at least 8 units, but no more than 250 units, is required to operate in the SmartGuard™ feature.
WARNING: Do not use the MiniMed™ 780G system until appropriate training has been received from a healthcare professional. Training is essential to ensure the safe use of the MiniMed™ 780G system.
WARNING: Do not use SG values to make treatment decisions, including delivering a bolus, while the pump is in Manual Mode. When the SmartGuard™ feature is active and you are no longer in Manual Mode, the pump uses an SG value, when available, to calculate a bolus amount. However, if your symptoms do not match the SG value, use a BG meter to confirm the SG value. Failure to confirm glucose levels when your symptoms do not match the SG value can result in the infusion of too much or too little insulin, which may cause hypoglycemia or hyperglycemia.
Pump therapy is not recommended for people whose vision or hearing does not allow for the recognition of pump signals, alerts, or alarms. The safety of the MiniMed™ 780G system has not been studied in pregnant women, persons with type 2 diabetes, or in persons using other anti-hyperglycemic therapies that do not include insulin. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, please consult https://www.medtronicdiabetes.com/important-safety-information#minimed-780g and the appropriate user guide at https://www.medtronicdiabetes.com/download-library